• Interventional Cardiology:
  • I began performing cardiac catheterization in1981, then coronary angioplasties in 1984, PCI in acute MI since 1988.  
  • I organized a 24/7 PCI acute care department for acute coronary syndromes since 1994. I took part in a number of collaborative studies about stable and unstable coronary artery disease, thrombolytic therapy, antiplatelet therapy, (see below), including the ongoing Ischemia Trial. 
  • Since 1985, I have performed percutaneous balloon mitral valvuloplasty for mitral stenosis, and aortic balloon valvuloplasty for aortic stenosis; recently I performed TAVI as a second operator.

• Studies about patients selection for ICD implantation, using MIBG imaging on top of recommended criteria : MISTIC study (PHRC), and ADMIRE-ICD (GE Health Care, Principal Investigator for France)

• Cardiac amyloidosis in Mutated TTR Familial Amyloidosis. I worked on this subject along with Pr David ADAMS, Pr Didier SAMUEL and Pr Dominique LE GULUDEC since 1994, within the French Referent Center for Rare Diseases Familial Amyloid Polyneuropathy-CRMR-NNERF since 2005. Our group assessed more than 600 patients with a pathogenic mutation, and treated 250 with liver transplantation. We assessed and published data about multimodality imaging (« bone » DPD scintigraphy, MIBG sympathetic innervation imaging, cardiac echography, cardiac MRI) for early detection of infiltrative cardiomyopathy, about prophylactic pacing for conduction disorders, and about the prognostic value of sympathetic and parasympathetic denervation. 

The lack of animal models precludes any pre-clinical study. Our group has been part of the very early assessment of new disease modifying therapies in phase III studies, focusing on the assessment of their cardiac effects:

• • Tafamidis, a stabilizer of Transthyretin  (Foldr’X studies). I am the Principal Investigator for France of the ongoing phase III randomized study of Tafamidis in Cardiac aTTR amyloidosis (ATTRACT B3461028-B3461045)
  • Antisense oligonucleotides (Inotersen-Ionis ISIS 420915-CS2).
  • mRNA silencers Patisiran and Revusiran (Alnylam) (ALN-TTR-002-SC Apollo Study with Patisiran  for amyloid neuropathies, and ALN-TTRSC-004 Endeavour randomized study with Revusiran for cardiac amyloidosis) I was the Principal Investigator for France of  Endeavour which was prematurely terminated.

• .